tbuckley/cabot-search huggingface dataset:
MicroRNA-mediated PTEN downregulation as a novel non-genetic mechanism of acquired resistance to PI3Kα inhibitors of head &amp; neck squamous cell carcinoma
Authors: Claudio Pulito, Sebastiano Vaccarella, Alina Catalina Palcau, Federica Ganci, Renata Brandi, Carlotta Frascolla, Andrea Sacconi, Valeria Canu, Anna Benedetti, Valentina De Pascale, Sara Donzelli, Anne-Sophie Fisch, Valentina Manciocco, Renato Covello, Fulvia Pimpinelli, Aldo Morrone, Francesco Fazi, Raul Pellini, Paola Muti, Jalna Meens, Christina Karamboulas, Anthony C Nichols, Sabrina Strano, Konrad Klinghammer, Ingeborg Tinhofer, Laurie Ailles, Giulia Fontemaggi, Giovanni Blandino
Journal: Drug Resistance Updates (2025)
Gut microbiota drives structural variation of exogenous probiotics to enhance colonization
Authors: Shuaiming Jiang, Shi Huang, Zeng Zhang, Wenyao Ma, Zhe Han, Yuan Song, Dongxue Huo, Weipeng Cui, Jiachao Zhang
Journal: Gut Microbes (2025)

Probiotics encounter colonization resistance from native gut microbiomes, affecting their effectiveness. Genetic engineering of probiotics lacks universal applicability, as gut microbiotas are highly individualized. Here, we employed probiotic Lactiplantibacillus plantarum HNU082 (Lp082) to test whether Lp082 gut-adapted mutants can resolve colonization resistance in a new gut environment. Relying on culture-based methods and metagenomics, two distinct evolutionary clades of Lp082 in mice gut were observed, where one clade, which acquired more mutations, exhibited a longer survival time. However, these Lp082 isolates carrying many single nucleotide variants (SNVs) still exhibited phenotypic inconsistencies, with 13 strains of enhanced acid resistance. Thus, nanopore sequencing was proposed to identify structural variations (SVs). Among them, 12 strains had the Cro/C1-type HTH DNA-binding domain insertion, which enhanced growth and reproduction under bile salt stress, thereby increasing colonization time and quantity in the gut. The gut domestication process can drive probiotics to undergo many SNVs and SVs, thereby enhancing their colonization ability, which provides new insights into the colonization mechanisms and offers an ecology-based strategy.
Geometric Adjustment of T Cell‐Sensitive Nanorobots for Enhanced Stability
Authors: Yoojin Lee, Dahae Kim, Taihyun Kim, Chae‐Won Moon, Hyungseok Yong, Sung‐eun Heo, Bumgyu Choi, Yoogyeong Oh, Woojin Choi, Kyungtae Park, Sang‐Jun Ha, Jinkee Hong
Journal: Advanced Healthcare Materials (2025)

Abstract Personalized dendritic cell (DC) based vaccines offer promising immunotherapeutic approaches for cancers and infectious diseases by leveraging living DCs to stimulate a patient's immune system through interactions with T cells. However, conventional DC‐based vaccines face significant challenges, including limited stability and short storage lifespan of the living cells. To overcome these limitations, smart artificial nanorobots, termed nano‐bone marrow dendritic cell (BMDC)‐originated T cell activators (nano‐BOTs) are developed by incorporating 1‐dimensional (1D) nanoparticles to enhance stability and activation efficacy. The use of 1D nanoparticles enables precise modulation of the geometric properties, resulting in significantly improved interactions with effector T cells. This innovative approach addresses the inherent limitations of traditional DC‐based vaccines and amplifies their ability to activate effector T cells. The advanced nanorobots exhibit exceptional stability and therapeutic potential, representing a transformative step toward personalized DC‐based vaccines in future biological therapeutics.
Extranodal diffuse large B‐cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study
Authors: Si‐Yuan Chen, Peng‐Peng Xu, Ru Feng, Guo‐Hui Cui, Li Wang, Shu Cheng, Rong‐Ji Mu, Hui‐Lai Zhang, Xiao‐Lei Wei, Yong‐Ping Song, Kai‐Yang Ding, Li‐Hua Dong, Zun‐Min Zhu, Shen‐Miao Yang, Xin Wang, Ting‐Bo Liu, Jian‐Da Hu, Xiao‐Yun Zheng, Ou Bai, Jing‐Yan Xu, Liang Huang, Wei Sang, Ke‐Qian Shi, Fan Zhou, Fei Li, Ai‐Bin Liang, Hui Zhou, Si‐Guo Hao, Hong‐Hui Huang, Bin Xu, Wen‐Bin Qian, Cai‐Xia Li, Zhi‐Ming Li, Chong‐Yang Wu, Xiao‐Bo Wang, Wen‐Yu Shi, Shu‐Ye Wang, Yu‐Yang Tian, Xi Zhang, Ke‐Shu Zhou, Li‐Juan Cui, Hui Liu, Huo Tan, Qing Leng, Dong‐Lu Zhao, Ting Niu, Wei‐Li Zhao
Journal: Cancer Communications (2025)

Abstract Background Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of aggressive non‐Hodgkin's lymphoma with distinct clinical and molecular heterogeneity. DLBCL that arises in extranodal organs is particularly linked to poor prognosis. This study aimed to determine the clinical and molecular characteristics of extranodal involvement (ENI) in DLBCL and assess the actual survival status of the patients. Methods In this population‐based cohort study, we investigated the clinical features of 5,023 patients newly diagnosed with DLBCL. Their clinical conditions, eligibility criteria, and sociodemographic details were recorded and analyzed. Gene panel sequencing was performed on 1,050 patients to discern molecular patterns according to ENI. Results The 2‐year overall survival (OS) rate was 76.2% [95% confidence interval (CI), 74.0%‐78.2%], and the 5‐year OS rate was 67.9% (95% CI, 65.2%‐70.4%). The primary treatment was immunochemotherapy with rituximab. Specific lymphoma involvement sites, especially the bones, bone marrow, and central nervous system, were identified as independent adverse prognostic factors. A high prevalence of non‐germinal center B‐cell (non‐GCB) phenotype and myeloid differentiation primary response 88 ( MYD88 )/ CD79B mutations were noted in lymphomas affecting the breasts, skin, uterus, and immune‐privileged sites. Conversely, the thyroid and gastrointestinal tract showed a low occurrence of non‐GCB phenotype. Remarkably, patients with multiple ENIs exhibited a high frequency of MYD88 , tet methylcytosine dioxygenase 2 ( TET2 ), CREB binding protein ( CREBBP ) mutations, increased MYD88 L265P and CD79B mutation (MCD)‐like subtypes, and poor prognosis. Genetic subtype‐guided immunochemotherapy showed good efficacy in subgroup analyses after propensity score matching with 5‐year OS and progression‐free survival rates of 85.0% (95% CI, 80.6%‐89.5%) and 72.1% (95% CI, 67.3%‐76.7%). Conclusions In the rituximab era, this large‐scale retrospective analysis from Asia confirmed the poor prognosis of DLBCL with multiple ENIs and underscored the efficacy of genetic subtype‐guided immunochemotherapy in treating extranodal DLBCL.
Ascites of patients with solid tumors shows distinct inflammatory patterns
Authors: Julia M. Berger, Martin Korpan, Carina Zierfuss, Katharina Syböck, Erwin Tomasich, Andreas Kienzle, Maria Koenig, Markus Kleinberger, Lynn Gottmann, Birgit Fendl, Cihan Ay, Johannes Pammer, Catharina Müller, Rudolf Oehler, Lorenz Balcar, Thomas Reiberger, Elisabeth S. Bergen, Barbara Niederdorfer, Matthias Preusser, Anna S. Berghoff
Journal: Cancer Communications (2025)
Novel oncolytic vaccinia virus armed with interleukin-27 is a potential therapeutic agent for the treatment of murine pancreatic cancer
Authors: Yangyang Jia, Yanru Wang, Guanghao Zhao, Yong Yang, Wenyi Yan, Ruimin Wang, Bing Han, Lihong Wang, Zhe Zhang, Lijuan Chen, Nicholas R Lemoine, Louisa S Chard Dunmall, Pengju Wang, Yaohe Wang
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background Pancreatic cancer has a complex immunosuppressive tumor microenvironment (TME), which is highly resistant to conventional therapies and emerging cancer immunotherapies. Oncolytic viruses are multifaceted killers of malignant tumors, which can selectively infect, replicate in and lyse tumor cells, release tumor-associated antigens to stimulate specific antitumor immune responses, and recruit immune cells into the TME, turning “cold” tumors “hot”. Here, we report a novel vaccinia virus (VV), VVLΔTKΔN1LΔA41L (with deletion of thymidine kinase (TK), N1L, and A41L genes) armed with interleukin 27 (IL-27), that can cure established tumors and promote long-term antitumor immunity in murine pancreatic cancer tumor models. Methods A novel oncolytic VV with deletion of the TK, N1L, and A41L genes, and expression of the red fluorescent protein (RFP) gene (VVL-TD-RFP) was constructed using CRISPR-Cas9-based homologous recombination. This virus was armed with IL-27, creating VVL-TD-IL-27. The characteristics of these viruses were evaluated in vitro using viral replication assays, cytotoxicity assays and ELISA. The antitumor effects of VVL-TD-IL-27 were evaluated using a variety of pancreatic cancer tumor models in vivo , and the mechanisms of antitumor effects were explored using flow cytometry, immunohistochemistry, ELISA and quantitative PCR. Results VVL-TD-RFP cured 71.4% of tumor-bearing mice, compared with 14.3% of animals treated with VVLΔTKΔN1L that does not have an A41L gene deletion. Efficacy was mainly dependent on elevated dendritic cell (DC) populations, activation of DC, CD86 + DC, and CD8 + effector memory T cells in the TME. Efficacy was further enhanced by arming VVL-TD-RFP with IL-27, which resulted in a cure rate of 100% and promoted long-term antitumor immunity. VVL-TD-IL-27 treatment increased the proportion of CD8 + TEM and decreased the proportion of regulatory T cells and macrophages in tumor tissues. It also polarized macrophages to an M1 phenotype in vivo . Furthermore, IL-27 exhibits strong anti-angiogenic effects. Conclusions VVL-TD-mIL-27 is a potential immunotherapy agent for the treatment of pancreatic cancer, and a clinical study of this virus is warranted.
Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein
Authors: Giulia Rotta, Eleonora Prodi, Frauke Seehusen, Matilde Bocci, Francesco Prisco, Ettore Gilardoni, Claudia Comacchio, Cornelia Halin, Emanuele Puca, Dario Neri, Sheila Dakhel Plaza
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background The administration of recombinant interleukin 2 (IL-2) in oncology is frequently hampered by dose-limiting toxicities, including potentially lethal vascular leak syndrome. Antibody-IL-2 fusion proteins capable of preferential tumor localization have shown encouraging signs of activity in clinical trials; however, they typically cause side effects shortly after intravenous administration, which may limit escalation to curative doses. There is an urgent need to engineer IL-2 products with “activity-on-demand” able to mask on-target off-tumor IL-2 activity without compromising therapeutic efficacy. Methods To design IL-2 biopharmaceuticals with “activity-on-demand”, which would be non-toxic on administration but regain activity at the tumor site, we explored the therapeutic potential of the co-administration of signaling inhibitors with matched pharmacokinetic properties. In this work, we used the tumor-homing F8-IL2 fusion protein, specific to a splice variant of fibronectin, and masked off-tumor toxicity by co-administration of upadacitinib, which rapidly clears from circulation. Vascular leak syndrome was monitored by histopathological analysis, the extent of peripheral edema, and cytokine levels. Immune profiling of the tumors and secondary lymphoid organs was performed by flow cytometry. Results In immunocompetent tumor-bearing mice, the combinatorial treatment significantly improved tolerability without any detectable loss of therapeutic activity, protecting the mice from body weight loss, uncontrolled systemic cytokine release, and severe vascular leak syndrome manifestations, including peripheral edema. F8-IL2 efficiently controlled tumor growth and retained its immunological activity within the neoplastic mass, as evidenced by the massive natural killer and cytotoxic T-cell infiltrates. Conclusions This study suggests that combinatorial treatments enable the administration of potentially curative doses of targeted IL-2 products while sparing healthy organs from life-threatening toxicities.
The cold immunological landscape of ATM-deficient cancers
Authors: Sonali Sinha, Victor Ng, Ardijana Novaj, Yingjei Zhu, Shu Yazaki, Xin Pei, Fatemeh Derakhshan, Fresia Pareja, Jeremy Setton, Flavie Naulin, Manuel Beltrán-Visiedo, Ethan Shin, Ana Leda F Longhini, Rui Gardner, Jennifer Ma, Kevin Ma, Anne Roulston, Stephen Morris, Maria Koehler, Simon Powell, Ezra Rosen, Lorenzo Galluzzi, Jorge Reis-Filho, Atif Khan, Nadeem Riaz
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background Mutations in genes encoding DNA repair factors, which facilitate mismatch repair, homologous recombination, or DNA polymerase functions, are known to enhance tumor immunogenicity. Ataxia telangiectasia mutated ( ATM ) is a central regulator of DNA double-strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. However, the consequences of ATM loss on tumor immunogenicity are poorly understood. Methods We generated isogenic ATM-null models using CRISPR in murine triple-negative breast (4T1) and colorectal (CT26) cancer cell lines. ATM inactivation was confirmed by PCR and western blot. Immune cell infiltrates were assessed by flow cytometry and immunohistochemistry in both murine tumors and human samples from breast and lung cancers (via The Cancer Genome Atlas and institutional cohorts). In vivo, the impact of ATM loss on tumor growth and response to immune checkpoint blockade (anti-programmed cell death protein-1 (PD-1)) was evaluated. Furthermore, we compared the effects of different DNA-damaging agents—including an ATR inhibitor (RP-3500), a PARP inhibitor (olaparib), and the topoisomerase II inhibitor etoposide—on interferon-stimulated gene (ISG) expression and immune modulation. Results We find that—in contrast to other DNA repair defects —ATM deficiency (1) fails to encourage immune effector cell infiltration into tumors, and (2) does not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with ATR inhibition. Assessing various DNA-damaging agents in Atm null tumors revealed a differential activation of type I interferon (IFN) signaling, with etoposide, a topoisomerase II inhibitor, emerging as the strongest activator of ISG under these conditions. Yet, PD-1-targeted immune checkpoint blockade does not bolster the therapeutic activity of etoposide in Atm -null syngeneic tumor models, nor does it modify the tumor microenvironment, suggesting that type I IFN signaling alone is insufficient to overcome immunosuppression in immunologically cold ATM null neoplasms. Conclusions ATM deficiency, while compromising DNA repair and enhancing sensitivity to radiation and ATR inhibition, does not increase tumor antigenicity or immunogenicity. Altogether, our results have important implications for the design of novel combination therapies for ATM null tumors and highlight the importance of antigenicity in the immunological consequences of defective DNA repair.
Spatial transcriptomics highlights B cells as key contributors to a complete and durable response to chemo-immunotherapy in a patient with resectable NSCLC
Authors: Nicla Porciello, Filippo Gallina, Giuseppe Frisullo, Francesca Fusco, Lorenzo D'Ambrosio, Vittoria Balzano, Francesca De Nicola, Paolo Visca, Lorenza Landi, Federico Cappuzzo, Paola Nistico
Journal: Journal for ImmunoTherapy of Cancer (2025)

Neoadjuvant chemo-immunotherapy has significantly improved the treatment landscape for patients with ALK/EGFR wt resectable non-small cell lung cancer (NSCLC), offering novel opportunities for translational and clinical investigations. By leveraging deep molecular profiling through spatial transcriptomics integrated with single-cell RNA-sequencing from public atlases, and serum proteomic profiling, we report a case of a patient with resectable NSCLC and a solitary synchronous brain metastasis showing a complete pathologic response after chemo-immunotherapy, and a durable event-free survival. The deep profiling of the tumor immune microenvironment of both pre-treatment brain metastasis and post-treatment primary lung tumor tissues unveiled a key role of B lymphocytes at different maturation state, spanning from naïve to plasma cells, in mediating tumor eradication. Notably, the formation of several tertiary lymphoid structures in the regression bed of post-treatment primary tumor was observed, suggesting the in situ generation of high-affinity antibody and specific immune memory response. This multimodal approach paves the way for the discovery of novel biomarkers at both tissue and systemic levels, fostering improved patient stratification and guiding clinical decisions on post-surgical treatment escalation or de-escalation.
Should Your PE Happen During Business Hours: Pert Usage and Temporal Variations
Authors: J. Vernejoul, D. Slagle, R. Gaaserud, N.E. Amoroso, R.M. Goldenberg, J. Horowitz, C. Jamin, E. Bondarsky, E. Yuriditsky, B. Taslakian, T. Maldonado, S.B. Brosnahan
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Evolution of Lung Transplant Patients Due to Interstitial Diseases
Authors: A.B. Llanos-Gonzalez, E. González Dávila, P. Pérez de Armas, N. Mesa León, V.S. Hernández García, L. Ferreiros de la Campa, S. De Lucas Altable, C. Martín García, E. Pérez Hernández, J. Abreu González, S. García Gil, O. Acosta, A. Pérez Rodríguez
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
The Effect of Prone Position-induced Lung Recruitment Is Independent From Its Effect on Perfusion and Gas Exchange: A Secondary Computed Tomography Analysis of a Controlled Circulatory Death Donor Model
Authors: M. Bosone, H. Chan, J. Wei, L. Menga, Y. Watanabe, M. Liu, S. Keshavjee, M. Cypel, L. Del Sorbo
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Anti-PD-1 and Anti-CD39 Induce Respective CD8 T Cell and Macrophage Responses at the Patient-derived Ex Vivo Tumor-border
Authors: T. Bargmann, S. Konzok, R. Liguori, M. Fuchs, C. Sommer, D. Schaudien, C. Schob, S. Halle, C. Werlein, P. Zardo, L. Neuebert, D.D. Jonigk, H.-G. Fieguth, F. Ferrazzi, K. Sewald, S. Dehmel, A. Braun
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Does Operator Experience Modify the Effect of Noninvasive Ventilation on Hypoxemia During Tracheal Intubation: A Post-hoc Analysis of the PREOXI Trial
Authors: P.J. Mead, K. Gibbs, J.D. Casey, M.W. Semler, B. Imhoff, A.A. Ginde, S.J. Halliday
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
How Do the Oxygen Saturation Values That Mechanically Ventilated ICU Patients Experience in Clinical Care Compare to the Personalized Targets That a Machine Learning Model Predicts Will Result in the Best Outcomes?
Authors: K.P. Seitz, A. Spicer, K.G. Buell, L. Wang, E.J. Graham Linck, B.D. Lloyd, K. Gray, B. Decoursey, D.J. Krasinski, E.M. Talbot, W.H. Self, T.W. Rice, J.D. Casey, M.M. Churpek, M.W. Semler, E.T. Qian
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Macrophage-Specific MicroRNA-193B Drives Lung Tumorigenesis by Reprogramming Immune Responses: Implications for Targeted Immunotherapy in Non-small Cell Lung Cancer (NSCLC)
Authors: K. Turkowski, S. Dizdarevic, M. Rieger, A. Weigert, T. Haselbauer, F. Grimminger, W. Seeger, S.S. Pullamsetti, R. Savai
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Screening for Systemic Autoimmune Rheumatic Disease-Associated Interstitial Lung Disease in Central and Eastern Europe
Authors: M. Sanzharovskaya, R. Bakenova, P. Baltzer, C. Codreanu, M. Koziar Vašáková, D. Lang, G. Nagy, W.J. Piotrowski, S. Pochepnia, E. Straka, C.L. Toma, M. Tomcik, M. Yessengeldinova, H. Prosch
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Physical Activity Monitoring as a Method to Quantify Post-discharge Physical Health Recovery in Critically Ill Children Who Survive Acute Respiratory Failure
Authors: A.B. Maddux, K.R. Miller, R. Greer, L. Dailey, L. Petruccelli, J. Laurin, C. Krekorian, P.M. Mourani, G. Kerby, M. Rosenfeld, R.S.S. Watson, E.Y. Killien
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Not All Hilar Adenopathy Is Sarcoidosis: A Rare Case of Mediastinal and Hilar Lymph Node Metastasis in Cervical Squamous Cell Carcinoma
Authors: H.M.A. Jeelani, S. Iqbal, R. Chowdhary, M. Ashraf, C. Castro
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
T Cell Specific Stat1 Drives Neutrophil Induced Lung Pathology During Klebsiella Pneumoniae Infection
Authors: A. Gupta, S. Kassab, Z. Xiong, A. Gheware, Z. Bou Reslan, P. Bhojraj, M.R. Rosengart, K. Chen, J. Lee
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Integrated Multi-omics Unraveled a Basal Cell-dependent Signature Predictor of Outcome and Immunotherapy Response in LUSC
Authors: J. Jia, R. Liu, B. Deng, E. Fiedler, A.B. Snkar, X. Guo, G.A. Giotopoulou, S.J. Behrend, Y. Liu, A.L.H. Tufman, None Yildirim, G.T. Stathopoulos, A.C. Schamberger, L. Asarian, I.E. Fernandez
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Risk Factors for and Prediction of 28-day In-hospital Mortality in Critically Ill Adults Undergoing Tracheal Intubation
Authors: A. Muhs, B. Imhoff, K.P. Seitz, E.T. Qian, S.C. DeMasi, M.E. Prekker, B.E. Driver, K. Gibbs, A.A. Ginde, W.H. Self, T.W. Rice, M.W. Semler, J.D. Casey
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Pneumocystis Pneumonia After Chimeric Antigen Receptor T-cell (CAR-T) Therapy: A Systematic Review and Meta-analysis
Authors: A. Diaz-Barba, B. Maryam, M. Jamil, M. Asif, B. Khanam, T. Al Juhaishi, J. Sassine
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Improving Weaning Outcomes: A Cohort Study of High-Flow Tracheal Therapy vs. Tracheostomy Mask
Authors: J. Alvarado, A.G. López-Rubio, Y. Torres-Suárez, D. Ortiz-Moreno, C.A. Pérez-Velázquez, L.M. Castillo-Morales, A.F. Mora-Salamanca
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Single Center Experience on Anti-Fibrotic (AF) Versus Immunosuppression (IS) in Connective Tissue-related Interstitial Lung Disease (CTD-ILD)
Authors: F.L. Irvin, L. Paoletti, T.P.M. Whelan, J.T. Huggins, R. Krishna, A.A. Menon
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
CT Airway-to-Lung Ratio Modifies the Impact of Indoor Air Pollution on Cardiac Autonomic Function in COPD
Authors: S. Raju, K. Koehler, B.M. Smith, H. Woo, A. Fawzy, A. Balasubramanian, N. Putcha, N.N. Hansel, M.C. Mccormack
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Impact of a Mechanical Insufflator-Exsufflator on the Need for Tracheal Suctioning in Intubated Patients - A Prospective Randomized Crossover Trial
Authors: A. Demoule, D. Hajage, E. Morawiec, J. Mayaux, M. Decavèle, M. Dres, M. Lecronier, M. Faure, T. Similowski, J. Gonzalez Bermejo, J. Delemazure
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Prevalence of Cancer in Patients With Positive Myositis Antibodies and Interstitial Lung Disease
Authors: P. Khamooshi, J. Peterson, C. Cook, A. Agarwal, O. Amoda, K. Akopyan, R. Reddy, C. Harden, D.C. Gomez Manjarres, F.M. Pais
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Electronic Nose Technology as Diagnostic Tool for Different Fibrotic Interstitial Lung Disease: The ILDnose Study
Authors: B. Formsma, C.C. Moor, I.G. Van Der Sar, L. Yazbeck, M. Polke, M. Kreuter, V. Cottin, P.L. Molyneaux, M.S. Wijsenbeek
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Dietary Fiber Modulates Lung Immunity and Immunotherapy Response in NSCLC
Authors: A. Czachor, M. Chang, Y. Li, A. Lukovnikova, F. Darawshy, C. Mccormick, R. Singh, B. Wu, D. Sterman, L. Segal, Q. Li
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Association of Glucagon-Like Peptide-1 Agonists and Mortality Among Patients With Idiopathic Pulmonary Fibrosis
Authors: E. Kosak Lopez, J.M. Martinez, Y. Gonzalez Moret, R. Leguizamon, A. Geller, M.D.J. Vera, P. Wattanachayakul, G. Eiger, S. Benzaquen
Journal: American Journal of Respiratory and Critical Care Medicine (2025)